Hamed C.
- Country
- France
- Department
- Oncologie
Research Overview
- Phase III Randomized Trial Evaluating Adjuvant Leuprorelin Acetate Therapy Post-Radical Prostatectomy in High-Risk Prostatic Adenocarcinoma Patients
- Evaluation of Adjuvant Pembrolizumab Versus Observation in Early Triple-Negative Breast Cancer with Pathologic Complete Response Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 9 of 86 partner sites.
Specializations
Breast cancer and endocrine-based treatment
Clinical research activity in ER+/HER2- metastatic breast cancer is centered on hormone-driven disease control, with attention to combining palbociclib and endocrine therapy and to treatment selection guided by circulating tumor DNA and ESR1 mutations.
- CDK4/6 inhibition
- Hormone therapy sequencing
- Molecular resistance markers
Interest also extends to adapting endocrine treatment strategies when resistance-associated genomic changes emerge during ongoing therapy.
Triple-negative breast cancer and immunotherapy
Research involvement includes early triple-negative breast cancer in the setting of deep response after neoadjuvant chemotherapy and pembrolizumab, with focus on post-surgical management and recurrence prevention.
- Immune checkpoint inhibition
- Pathologic complete response
- Recurrence-free survival
The therapeutic interest lies in refining the role of adjuvant pembrolizumab after major response to preoperative treatment.
Prostate cancer and hormonal recurrence prevention
Clinical trial activity also covers prostatic adenocarcinoma with high risk of recurrence, emphasizing long-term disease control after radical prostatectomy through adjuvant hormonal treatment.
- Androgen deprivation therapy
- Postoperative recurrence risk
- Metastasis-free survival
This area reflects interest in sustained hormonal suppression for patients with aggressive localized disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.